[go: up one dir, main page]

DE60135087D1 - Dipeptidnitrile als inhibitoren von cathepsin k - Google Patents

Dipeptidnitrile als inhibitoren von cathepsin k

Info

Publication number
DE60135087D1
DE60135087D1 DE60135087T DE60135087T DE60135087D1 DE 60135087 D1 DE60135087 D1 DE 60135087D1 DE 60135087 T DE60135087 T DE 60135087T DE 60135087 T DE60135087 T DE 60135087T DE 60135087 D1 DE60135087 D1 DE 60135087D1
Authority
DE
Germany
Prior art keywords
dipeptid
cathepsin
nitrile
inhibitors
dipeptid nitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60135087T
Other languages
English (en)
Inventor
Martin Missbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60135087D1 publication Critical patent/DE60135087D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE60135087T 2000-02-10 2001-02-08 Dipeptidnitrile als inhibitoren von cathepsin k Expired - Lifetime DE60135087D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0003111.2A GB0003111D0 (en) 2000-02-10 2000-02-10 Organic compounds
PCT/EP2001/001359 WO2001058886A1 (en) 2000-02-10 2001-02-08 Dipeptide nitrile cathepsin k inhibitors

Publications (1)

Publication Number Publication Date
DE60135087D1 true DE60135087D1 (de) 2008-09-11

Family

ID=9885359

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60135087T Expired - Lifetime DE60135087D1 (de) 2000-02-10 2001-02-08 Dipeptidnitrile als inhibitoren von cathepsin k

Country Status (30)

Country Link
US (4) US6642239B2 (de)
EP (1) EP1254124B1 (de)
JP (1) JP3942895B2 (de)
KR (1) KR100544553B1 (de)
CN (2) CN1183122C (de)
AR (1) AR029466A1 (de)
AT (1) ATE402930T1 (de)
AU (1) AU764334B2 (de)
BR (1) BR0108118A (de)
CA (1) CA2396158C (de)
CO (1) CO5261578A1 (de)
CZ (1) CZ20022721A3 (de)
DE (1) DE60135087D1 (de)
ES (1) ES2310177T3 (de)
GB (1) GB0003111D0 (de)
HU (1) HUP0300148A3 (de)
IL (1) IL150406A0 (de)
MX (1) MXPA02007768A (de)
MY (1) MY122826A (de)
NO (1) NO20023780L (de)
NZ (1) NZ519940A (de)
PE (1) PE20020220A1 (de)
PL (1) PL200119B1 (de)
PT (1) PT1254124E (de)
RU (2) RU2265601C2 (de)
SK (1) SK11462002A3 (de)
TR (1) TR200201752T2 (de)
TW (1) TWI258473B (de)
WO (1) WO2001058886A1 (de)
ZA (1) ZA200206218B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723407D0 (en) * 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
JP2002539191A (ja) 1999-03-15 2002-11-19 アクシス・ファーマシューティカルズ・インコーポレイテッド プロテアーゼ阻害剤としての新規化合物及び組成物
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
MXPA03005601A (es) 2000-12-22 2004-12-02 Axys Pharm Inc Nuevos compuestos y composiciones como inhibidores de catepsina.
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
RS19504A (sr) 2001-09-14 2007-02-05 Aventis Pharmaceuticals Inc., Nova jedinjenja i kompozicije kao inhibitori katepsina
US6977256B2 (en) 2001-11-14 2005-12-20 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin S inhibitors
IL163748A0 (en) * 2002-03-05 2005-12-18 Merck Frosst Canada Inc Cathepsin cysteine protease inhibitors
US20060122184A1 (en) * 2002-12-05 2006-06-08 Axys Pharmaceuticals, Inc. Cyanomethyl derivatives as cysteine protease inhibitors
JP4690319B2 (ja) * 2003-06-30 2011-06-01 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害剤
MXPA06000790A (es) * 2003-07-21 2006-04-07 Novartis Ag Combinaciones de un inhibidor de catepsina k y un bisfofonato en el tratamiento de metastasis osea, crecimiento de tumor y perdida osea inducida por tumor.
KR20060107792A (ko) * 2003-11-19 2006-10-16 노파르티스 아게 중증 골 소실 질환의 치료를 위한 카텝신 ｋ 억제제의 용도
EP1701960B1 (de) 2004-01-08 2010-03-17 Medivir Aktiebolag Inhibitoren von cysteinprotease
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
NZ555826A (en) 2004-12-06 2009-11-27 Univ California Methods for improving the structure and function of arterioles
GB0427380D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
EP1841419A4 (de) * 2005-01-19 2009-02-25 Merck Frosst Canada Ltd Cathepsin-k- und adipositas-inhibitoren
EP1841730A4 (de) * 2005-01-19 2010-10-27 Merck Frosst Canada Ltd Cathepsin-k-inhibitoren und atherosklerose
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
GB0517637D0 (en) * 2005-08-30 2005-10-05 Novartis Ag Organic compounds
US8829209B2 (en) 2006-01-11 2014-09-09 Seikagaku Corporation Cycloalkylcarbonylamino acid ester derivative and process for producing the same
JP3975226B2 (ja) * 2006-01-11 2007-09-12 生化学工業株式会社 シクロアルキルカルボニルアミノ酸誘導体及びその製造方法
JP4047365B2 (ja) 2006-01-11 2008-02-13 生化学工業株式会社 シクロアルカンカルボキサミド誘導体及びその製造方法
AU2007253796A1 (en) * 2006-05-22 2007-11-29 Velcura Therapeutics, Inc. Use of Cathepsin K antagonists in bone production
GB0614046D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614044D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614053D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
KR20100023948A (ko) 2007-06-08 2010-03-04 닛뽕 케미파 가부시키가이샤 뇌동맥류의 치료 또는 예방약
BRPI0702541A2 (pt) 2007-06-21 2009-02-10 Petroleo Brasileiro Sa processo de craqueamento catalÍtico para produÇço de diesel a partir de sementes de oleaginosas
US7893067B2 (en) 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
JPWO2009054454A1 (ja) * 2007-10-24 2011-03-03 国立大学法人 東京医科歯科大学 カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤
WO2009076490A1 (en) * 2007-12-12 2009-06-18 Velcura Therapeutics, Inc. Use of cathepsin l antagonists in the treatment of bone disease
WO2009087379A2 (en) 2008-01-09 2009-07-16 Amura Therapeutics Limited Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases
EP2262783A2 (de) * 2008-02-21 2010-12-22 Sanofi-Aventis Kovalent bindende sonden zur bilddarstellung
GB0817425D0 (en) * 2008-09-24 2008-10-29 Medivir Ab Protease inhibitors
US20100298507A1 (en) * 2009-05-19 2010-11-25 Menschig Klaus R Polyisobutylene Production Process With Improved Efficiencies And/Or For Forming Products Having Improved Characteristics And Polyisobutylene Products Produced Thereby
AU2012257779A1 (en) 2011-05-16 2013-11-28 Bayer Intellectual Property Gmbh Use of cathepsin K inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure
EP2537532A1 (de) 2011-06-22 2012-12-26 J. Stefan Institute Cathepsinbindende Verbindungen, die an ein Nanogerät gebunden sind, und deren diagnostische und therapeutische Verwendung
US9593138B2 (en) 2012-10-05 2017-03-14 Wayne State University Nitrile-containing enzyme inhibitors and ruthenium complexes thereof
EP3009444B1 (de) 2013-06-14 2017-12-20 Seikagaku Corporation Alpha-oxoacyl-amino-caprolactamderivat
EP3009425B1 (de) 2013-06-14 2018-06-06 Seikagaku Corporation Alpha-oxoacylaminocaprolactam

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3467691A (en) 1964-04-22 1969-09-16 Tsutomu Irikura N-(n-acylaminoacyl)-aminoacetonitriles
US5206249A (en) 1991-03-27 1993-04-27 Du Pont Merck Pharmaceutical Company Bis-naphthalimides containing amino-acid derived linkers as anticancer agents
EP0547699A1 (de) 1991-12-19 1993-06-23 Merck & Co. Inc. Peptidylderivate als Inhibitoren von Interleukin-1-Beta-konvertierenden Enzymen
JP3283114B2 (ja) 1992-09-07 2002-05-20 クミアイ化学工業株式会社 縮合ヘテロ環誘導体及び農園芸用殺菌剤
JP2848232B2 (ja) 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
WO1994025432A1 (fr) 1993-04-28 1994-11-10 Kumiai Chemical Industry Co., Ltd. Derive amide d'amino acide, bactericide horticole, et procede de production
EP0714293A4 (de) * 1993-07-30 1999-04-07 Smithkline Beecham Corp 3-cyano-3-(3,4-disubstituierte)phenylcyclohexyl-1-carboxylate
JPH09504302A (ja) 1993-11-01 1997-04-28 日本チバガイギー株式会社 エンドセリン・レセプター・アンタゴニスト
US5486623A (en) * 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
IL112759A0 (en) * 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
EP0749418B1 (de) 1994-03-10 2000-08-30 G.D. Searle & Co. L-n6-(1-iminoethyl)lysin - derivate und ihre verwendung als no-synthase - inhibitoren
US5614649A (en) * 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5804560A (en) 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
AU5687396A (en) * 1995-04-21 1996-11-07 Novarits Ag N-aroylamino acid amides as endothelin inhibitors
AU1595997A (en) 1996-01-26 1997-08-20 Smithkline Beecham Plc Thienoxazinone derivatives useful as antiviral agents
AU3359697A (en) 1996-07-08 1998-02-02 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
AU729133B2 (en) 1996-11-22 2001-01-25 Elan Pharmaceuticals, Inc. N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
GB9723407D0 (en) * 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
SK6572000A3 (en) 1997-11-05 2000-10-09 Novartis Ag Dipeptide nitriles, process for the preparation thereof, their use as medicaments and pharmaceutical composition comprising them
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
EP1155010A1 (de) 1999-02-20 2001-11-21 AstraZeneca AB Acetamido-acetonitril-derivate als cathepsin l- oder cathepsin s-inhibitoren
EP1155011A1 (de) 1999-02-20 2001-11-21 AstraZeneca AB Di- und tripeptidnitril-derivate als inhibitoren von cathepsin l und cathepsin s
WO2000051998A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
JP2002539191A (ja) 1999-03-15 2002-11-19 アクシス・ファーマシューティカルズ・インコーポレイテッド プロテアーゼ阻害剤としての新規化合物及び組成物
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
MXPA02002873A (es) * 1999-09-16 2002-08-30 Axys Pharm Inc Compuestos y composiciones farmaceuticas como inhibidores de la catepsina s.
JP2001139320A (ja) * 1999-11-05 2001-05-22 Asahi Glass Co Ltd 球状シリカゲルの製造方法
CA2395179A1 (en) * 1999-12-24 2001-07-05 F. Hoffmann-La Roche Ag Nitrile derivatives as cathepsin k inhibitors
JP2003525874A (ja) * 2000-01-06 2003-09-02 メルク フロスト カナダ アンド カンパニー プロテアーゼ阻害剤としての新規化合物および組成物
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
BR0108118A (pt) 2003-02-25
US6642239B2 (en) 2003-11-04
CN1398260A (zh) 2003-02-19
RU2005108133A (ru) 2006-09-10
EP1254124B1 (de) 2008-07-30
RU2293732C2 (ru) 2007-02-20
NO20023780D0 (no) 2002-08-09
ATE402930T1 (de) 2008-08-15
MXPA02007768A (es) 2002-10-11
CN1636980A (zh) 2005-07-13
PL200119B1 (pl) 2008-12-31
RU2002123350A (ru) 2004-01-10
US20050267129A1 (en) 2005-12-01
HK1050197A1 (en) 2003-06-13
CA2396158A1 (en) 2001-08-16
AU764334B2 (en) 2003-08-14
MY122826A (en) 2006-05-31
ZA200206218B (en) 2003-08-05
NO20023780L (no) 2002-08-09
US20010016207A1 (en) 2001-08-23
EP1254124A1 (de) 2002-11-06
GB0003111D0 (en) 2000-03-29
TR200201752T2 (tr) 2002-10-21
US20070191392A1 (en) 2007-08-16
SK11462002A3 (sk) 2003-01-09
AU4642601A (en) 2001-08-20
KR20020072310A (ko) 2002-09-14
CA2396158C (en) 2010-02-02
JP3942895B2 (ja) 2007-07-11
KR100544553B1 (ko) 2006-01-24
US20030203919A1 (en) 2003-10-30
PT1254124E (pt) 2008-11-03
RU2265601C2 (ru) 2005-12-10
JP2003522764A (ja) 2003-07-29
WO2001058886A1 (en) 2001-08-16
IL150406A0 (en) 2002-12-01
TWI258473B (en) 2006-07-21
HUP0300148A2 (en) 2003-05-28
AR029466A1 (es) 2003-07-02
CN1183122C (zh) 2005-01-05
ES2310177T3 (es) 2009-01-01
CO5261578A1 (es) 2003-03-31
HUP0300148A3 (en) 2005-04-28
PL357901A1 (en) 2004-07-26
PE20020220A1 (es) 2002-03-25
CZ20022721A3 (cs) 2002-11-13
NZ519940A (en) 2004-02-27

Similar Documents

Publication Publication Date Title
DE60135087D1 (de) Dipeptidnitrile als inhibitoren von cathepsin k
DE60321324D1 (de) Sulfonylaminoderivate als neue inhibitoren von histondeacetylase
ATE435211T1 (de) Imidazolidinone als ns3-serin protease inhibitoren von hepatitis c virus
DE60221977D1 (de) Pro-pharmakon von cox-2-inhibitoren
EP1272467A4 (de) Kathepsin-zystein-proteasenhemmer
DE60138717D1 (de) Peptidomimetika als protease inhibitoren
NO20034045D0 (no) Metallproteinase-inhibitorer
DE60211601D1 (de) Bereitstellung von positionsabhängigen Inhalten
EP1294513A4 (de) Lokalisationsspezifische kovalente biokonjugation von proteinen
NO20034032D0 (no) Metallproteinase-inhibitorer
DK1458447T3 (da) Kombination af cytokrom-p450-beroende proteasinhibitorer
DE60126814D1 (de) Inhalation von stickoxid
DE60210612D1 (de) N-formylhydroxylamin verbindungen als inhibitoren von pdf
ATE260274T1 (de) Furanonderivate als inhibitoren von cathepsin s
DE50113294D1 (de) Hochselektive inhibitoren des urokinase-plasminogenaktivators
ATE429431T1 (de) 2-amino-benzoxazol-suphonamide als breitspektrum- hiv-protease-inhibitoren
IT1324892B (it) Miscele di agenti stabilizzanti
DE60117938D1 (de) Vorspannen von Bauteilen
IT1324893B (it) Miscele di agenti stabilizzanti
DE60031450D1 (de) Polymorph v von torasemid
DE60007360T2 (de) Amorphe modifikation von torasemid
NO20025005D0 (no) Proteaseinhibitorer
NO20032328D0 (no) Proteaseinhibitorer
EP1674100A4 (de) Angiogenesehemmer
DE60227914D1 (de) Extraktive aufreinigung von lipopeptidantibiotika

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN